Fwd: Clinical trial for men with advanced prostate cancer progressing after chemo and hormone therapy

[Guest guest]

From US TOO International:

AFFIRM (A Study Evaluating the EFFicacy and Safety of

Investigational

DRug MDV3100 in Men with Advanced Prostate Cancer), a new late-stage

clinical trial now enrolling patients, will evaluate the efficacy

and

safety of the investigational drug MDV3100 as a treatment for

advanced

prostate cancer – specifically a type known as hormone-resistant

prostate cancer. The study will evaluate the impact of MDV3100 on

survival and other factors, including quality of life.

*About MDV3100*

The first triple-acting, oral anti-androgen, MDV3100 has been

shown in

preclinical studies to provide more complete suppression of the

androgen

receptor pathway than the most commonly used anti-androgen,

bicalutamide. MDV3100 slows growth and induces cell death in

bicalutamide-resistant cancers via three complementary actions –

MDV3100

blocks testosterone from binding to the androgen receptor, impedes

movement of the androgen receptor to the nucleus of prostate cancer

cells and inhibits binding to DNA. Preclinical data published in

Science

demonstrated that MDV3100 is superior to bicalutamide in each of

these

three actions.

*About the AFFIRM Study*

AFFIRM will enroll approximately 1,200 patients at sites in the

United

States and Canada, as well as in Europe, South America, Australia

and

South Africa. The study will test the efficacy and safety of

MDV3100 in

men with hormone-resistant prostate cancer that has progressed after

chemotherapy.

Patients who were previously treated with the chemotherapy drug

docetaxel may be eligible for the study. Two-thirds of patients will

randomly be assigned to receive MDV3100 while 1/3 will receive

placebo

(sugar pill), which does not contain active medicine.

For more information on eligibility and enrollment, patients can

call

the AFFIRM study hotline toll-free at 1- or visit

www.affirmtrial.com

<http://www.ustooevents.org/site/R?i=1gHA-83CfSoNM9dKMgQpcw..>.

See flyer here

<http://www.ustooevents.org/site/R?i=Xs1EVP3eoHiClNMV0dqaJg..>.

I hope you find this type of information useful. Please feel free to

forward this message along to other men you know who are dealing

with

late-stage prostate cancer, or to physicians who might be

interested in

sharing the information with their other patients.

Sincerely,

Tom Kirk

President & CEO

Us TOO International

tom@...

National Health Council Logo 3.23.09

<http://www.ustooevents.org/site/R?i=nvib-oS3LbUexkjifYrv2w..>

<http://www.ustooevents.org/site/R?i=_E_FQqAV_iOuVg1fZWnK-g..>

<http://www.ustooevents.org/site/R?i=RZVqpPgWk9m13F2ckpc__g..>

<http://www.ustooevents.org/site/R?i=TATSpV64zj6cwoG5IwtE3A..>

Facebook Badge 120px

<http://www.ustooevents.org/site/R?i=YiB9t6adGghhlbFr5m2mog..>

Myspace 125px

<http://www.ustooevents.org/site/R?i=j_O_aBEB7jv-VE1HDJbipg..>

<http://www.ustooevents.org/site/R?i=Fc7RpWNY9pmx9GIHtNGU7Q..>

<http://www.ustooevents.org/site/R?i=4Z2vuX9mlpCNHyT_iOf8Yw..>